Brief: Edgewise Therapeutics Doses First Patient In Phase 2 Equinox-Hfpef Trial Of Edg-15400
08/10/2026 13:18
BRIEF-Edgewise Therapeutics Doses First Patient In Phase 2 Equinox-Hfpef Trial Of Edg-15400 Oct 8 (Reuters) - Edgewise Therapeutics, Inc. EWTX.O:
EDGEWISE THERAPEUTICS DOSES FIRST PATIENT IN PHASE 2 EQUINOX-HFPEF TRIAL OF EDG-15400
Source text: ID:nPnS4kB0a
Further company coverage: EWTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edgewise Therapeutics
See all newsBrief: Edgewise Therapeutics Doses First Patient In Phase 2 Equinox-Hfpef Trial Of Edg-15400
Edgewise Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Edgewise Therapeutics Q2 net loss widens on higher expenses
Brief: Edgewise Therapeutics Q2 Operating Income USD -61.943 Million
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending